Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intradermal vaccination with rBCG-N-RSV that expresses the N protein of the respiratory syncytial virus (RSV)”In the company’s words, NCT07762014 on ClinicalTrials.gov
- Tested for
- Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention
- Main trialPhase 2
- “This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.”In the company’s words, NCT07762014 on ClinicalTrials.gov
Other drugs for Respiratory Syncytial Virus Infection Prevention
- RSVPreF3 OA vaccineGSK · Phase 3
- Human interferon α1b InhalationKexing Biopharm Co., Ltd. · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- S-337395Shionogi · Phase 2
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
Coming up1
- 7 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 7 Sep 2027 | rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026